ZA200301064B - Pyrazole derivatives and their use as protein kinase inhibitors. - Google Patents

Pyrazole derivatives and their use as protein kinase inhibitors. Download PDF

Info

Publication number
ZA200301064B
ZA200301064B ZA200301064A ZA200301064A ZA200301064B ZA 200301064 B ZA200301064 B ZA 200301064B ZA 200301064 A ZA200301064 A ZA 200301064A ZA 200301064 A ZA200301064 A ZA 200301064A ZA 200301064 B ZA200301064 B ZA 200301064B
Authority
ZA
South Africa
Prior art keywords
pyrazol
cyclobutyl
acetamide
phenyl
cis
Prior art date
Application number
ZA200301064A
Inventor
Cooper Christopher Blair
Helal Christopher John
Sanner Mark Allen
Travis T Wager
Original Assignee
Pfeizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeizer Products Inc filed Critical Pfeizer Products Inc
Publication of ZA200301064B publication Critical patent/ZA200301064B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Field of the Invention i The subject invention relates to pyrazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present invention act as inhibitors of cyclin-dependent protein kinase enzymes cdk5 {cyclin-dependent protein kinase 5) and cdk2 (cyclin-dependent protein kinase 2). The compounds of the present invention also are inhibitors of the enzyme GSK-3 (glygocen synthase kinase-3) enzyme.
Background of the Invention
The serine/threonine kinase cdk5 along with its cofactor p25 (or the longer cofactor, p25) has been linked to neurodegenerative disorders, and inhibitors of cdk&/p25 (or cdk5/p35) are therefore useful for the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, stroke, or Huntington's disease. Treatment of such neurodegenerative disorders using cdk5 inhibitors is supported by the finding that cdk5 is involved in the phosphorylation of tau protein (J. Biochem, 117, 741-749 (1995)). cdk5 also phosphorylates Dopamine and Cyclic AMP-Regulated Phosphorprotein (DARPP-32) at threonine 75 and is thus indicated in having a role in dopaminergic neurotransmission (Nature, 402, 669-671 (1999)).
The serine/threonine kinase cdk2 is essential for normal cell cycling and plays a critical role in disorders arising from abnormal cell cycling, a common characteristic of many oncological disorders. Inhibitors of cdk2 are therefore useful for the treatment of various types of cancer and other diseases or conditions related to abnormal cell growth (Meijer, et al.,
Properties and Potential-applications of Chemical Inhibitors of Cyclin-dependent Kinsases,
Pharmacology & therapeutics, 82 (2-3), 279-284 (1999); Sausville, et al., Cyclin-dependent
Kinases: Initial Approaches to Exploit a Novel Therapeutic Target, Pharmacology & therapeutics 82 (2-3) 285-292 (1999)).
GSK-3 is a serine/threonine protein kinase. It is one of several protein kinases which phosphorylate glycogen synthase (Embi, et al., Eur. J. Biochem. 107:519-527 (1980); . Hemmings, et al., Eur. J. Biochem. 119:443-451 (1982)). GSK-3 exists in two isoforms, o and " B, in vertebrates, reported as having a monomeric structure of 49kD and 47kD respectively. . Both isoforms phosphorylate muscle glycogen synthase (Cross, et al., Biochemical Journal 303: 21-26 (1994)). The amino acid identity among GSK-3 species homologs has been indicated to be in excess of 98% within the catalytic domain (Plyte, et al., Biochim. Biophys.
Acta 1114:147-162) (1992)). Due to a remarkably high degree of conservation across the ) phylogenetic spectrum, a fundamental role of GSK-3 in cellular processes is suggested.
GSK-3 has been implicated in numerous different disease states and conditions. For ’ example, Chen, et al, Diabetes 43: 1234-1241 (1994) have suggested that an increase in GSK-3 activity can be important in Type 2 diabetes. Increased GSK-3 expression in diabetic muscle is also though to contribute to the impaired glycogen synthase activity and skeletal muscle insulin resistance present in Type 2 diabetes (Nikoulina, et al., Diabetes 49: 263-271 (2000)). Also, a higher activity of a type 1 protein phosphatase measured in immotile sperm was attributed to higher GSK-3 activity and was indicated as responsible for holding the sperm motility in check (Vijayaraghavan, et al. Biology of Reproduction 54: 709-718 (19986)).
Vijayaraghavan et al. indicate that such resulis suggest a biochemical basis for the development and regulation of sperm motility and a possible physiological role for a protein phosphatase 1/inhibitor 2/GSK-3 system. GSK-3 activity has also been associated with
Alzheimer's disease and mood disorders such as bipolar disorder (WO 97/41854). Among other conditions, GSK-3 has furthermore been implicated in hair loss, schizophrenia, and neurodegeneration, including both chronic neurodegenerative diseases (such as Alzheimer’s, supra) and neurotrauma, for example stroke, traumatic brain injury, and spinal cord trauma.
Summary of the invention
This invention provides compounds of the formula
H
N- H
AN N—RI—R*
Rr? 1 wherein R' is a straight chain or branched (C,-Cg)alkyl, a straight chain or branched (C,-
Cslalkenyl, a straight chain or branched (C,-Cg)alkynyl, (C5-Cg)cycioalkyl, (C4-Cg)cycloatkenyl, (3- 8 membered) heterocycloalkyl, (Cs-C,,)bicycloalkyl, (C,~C;,)bicycloalkenyl, or (5-11 membered) heterobicycloalkyl; and wherein R' is optionally substituted with from one to six substituents R3 ) independently selected from F, Cl, Br, 1, nitro, cyano, -CF; -NR'R® -NR'C(=O)R® -
NR’C(=0)OR?, -NR’C(=O)NR®R?, -NR’S(=0),R%, -NR’S(=0),NR°R®, -OR’, -OC(=O)R’, - ) OC(=0)OR’, -C(=Q)OR’, -C(=O)R’, -C(=O)NR'R®, -OC(=O)NR’R®, -OC(=0)SR’, -SR’, -
S(=0)R’, -8(=0),R, -S(=0),NR'R?, and R;
R?is H, F, -CH,, -CN, or -C(=0)OR7;
R3? is -C(=0)NR®-, -C(=0)0O-, -C(=O)(CR"R""),-, or -(CRR"), -;
R* is a straight chain or a branched (C,-Cg)alkyl, a straight chain or a branched (C,- : Cylalkenyl, a straight chain or branched (C,-C, alkynyl), (C5-Cg)eycloalkyl, (C,-Cy)eycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,,)bicycloalkyl, (C,-C,,)bicycloalkeny!, (5-11 membered) ' heterobicycloalkyl, (C¢-C,,)aryl, or (5-14 membered) heteroaryl; and wherein R* is optionally substituted with from one to three substitutents R® independently selected from F, Cl, Br, I, nitro, cyano, -CF,; -NR'R®, -NR'C(=O)R?, -NR'C(=O)OR®, -NR'C(=O)NR®R®, -NR’S(=0).,R°, -NR’S(=0),NR®R®, -OR’, -OC(=0)R’, -OC(=0)OR’, -C(=0O)OR’, -C(=0)R’, -C(=O)NR'R?, -OC(=O)NR'R®, -OC(=0)SR’, -SR7, -S(=0)R’, -S(=0),R’, -S(=0),NR'R?, or R’; each R’, R%, and R° is independently selected from H, straight chain or branched (C-
Cgalkyl, straight chain or branched (C,-Cg)alkeny), straight chain or branched (C.-C, alkynyl), (C4-Cy)eycloalkyl, (C,-Cg)cycloalkenyl, (3-8 membered) heterocycloalkyl, (C.-C, )bicycloalkyl, (C,-C,,)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C¢C,,)aryl, and (5-14 membered) heteroaryl, wherein R?, R8, and R® are each independently optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, NO, -CN, -CF,; -NR"“R", 156 -NR"C(=O)R'", -NR'C(=O)OR", -NR™C(=O)NR''R", -NR'S(=0),R", -NR"S(=0),NR'"'R", -OR", -OC(=0O)R", -OC(=O)OR™, -OC(=O)NR'R", -OC(=0)SR?, -SRY, -S(=0)RY, -5(=0),R'°, -S(=0),NR"R", -C(=O)R'", -C(=0)OR", -C(=O)NR™R"", and R'’, or, when R” and R® are as in NR'R, they may instead optionally be connected to form with the nitrogen of NR’R® to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further heteroatoms independently selected from N, O, and S; each RY, R", and R* is independently selected from H, straight chain or branched (C,-
Ce)alkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cq alkynyl), (C5-Ce)cycloalkyl, (C,-Cg)cycioalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,,)bicycloalkyl, (C;-Cyy)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C¢-Cy,)aryl, and (5-14 membered) heteroaryl, wherein R', R", and R'? are each independently optionally substituted with from one to six substituents independently selected from F, Ci, Br, I, NO,, -CN, -CF;, -NR™R", -NRPC(=0)R", -NR"C(=0)ORY, -NR“C(=O)NR"R', -NR'S(=0),R", -NR“S(=0).NR"R', -OR"®, -OC(=0)R™, -OC(=0)OR™, -OC(=O)NR¥R", -OC(=O)SR®™, -SR™, -S(=O)R®, -S(=0).R"%, -S(=0),NR®R", -C(=0)R"?, -C(=0)OR", -C(=0)NR™R", and R'*; ’ each R™ R™, and R" is independently selected from H, straight chain or branched (C,-
Cglalkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cg alkynyl), * (C3-Ce)cycloalkyl, (C,-Cgloycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-Cy,)bicycloalkyl, (C;-Cy)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C4-C,o)aryl, and (5-14 membered) heteroaryl, wherein R"™, R™, and R"™ are each independently optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, NO,, -CN, -CF,;, -NR"R"
-NR*®C(=0)R", -NR™C(=O)OR", -NR'®C(=0)NR"R'™, -NR"®S(=0),R", -NR®S(=0),NR""R" : -OR'™ -OC(=O)R'™, -OC(=O)OR', -OC{=O)NR™R", -OC(=0)SR'™®, -SR*, -S(=O)R*, -S(=0),R™, -S(=0},NR"R", -C(=0)R'¢, -C(=0)OR'®, -C(=O)NR"*R", and R® ' each R', R", and R" is independently selected from H, straight chain or branched (C:- Cg)alkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cq alkynyl), (C4-Cy)eycloalkyl, (C,-Cg)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,,)bicycloalky!, (C,-C,,)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C4-C,,)aryl, and (5-14 membered) heteroaryl; nis 0, 1,2, or 3; wherein R" and R" in -C(=0)(CR"R"),- and -(CR'R""),- are for each iteration of n defined independently as recited above; and phamaceutically acceptable salts thereof.
Amino-substituted pyrazoles can exist as mixtures of tautomeric isomers in equilibrium with one another. The present invention includes all such tautomers of compounds of formula 1, and references herein to compounds of formula 1, uniess otherwise indicated, encompass also the tautomers of compounds of formula 1.
Compounds of formula 1 of the invention are inhibitors of serine/threonine kinases, especially cyclin-dependent kinases such as cdk5 and cdk2, and are useful for the treatment of neurodegenerative disorders and other CNS disorders, and of abnormal cell growth, including cancer. The compounds of formula 1 are particularly useful in inhibiting cdk5. The compounds of formula 1 are also useful as inhibitors of GSK-3.
The term “alkyl”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl.
The term “alkenyl”, as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyi.
The term “alkynyl”, as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl. ‘ The term “cycloalkyl”, as used herein, unless otherwise indicated, includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above. Examples of ‘ cycloalkyl inciude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. “Bicycloalkyl” groups are non-aromatic saturated carbocyclic groups consisting of two rings, wherein said rings share one or two carbon atoms. For purposes of the present invention, and unless otherwise indicated, bicycloalky! groups include spiro groups and fused ring groups. Examples of bicycloalkyl groups include, but are not limited to, bicyclo-[3.1.0]- ) hexyl, norbornyl, spiro[4.5]decy!, spiro[4.4]nonyl, spiro[4.3Joctyl, and spiro[4.2]heptyl. “Cycloalkenyl” and “bicycloalkenyl” refer to non-aromatic carbocyclic cycloalkyl and * bicycloalkyl moieties as defined above, except comprising one or more carbon-carbon double bonds connecting carbon ring members (an “endocyclic” double bond) and/or one or more carbon-carbon double bonds connecting a carbon ring member and an adjacent non-ring carbon {an “exocyclic” double bond). Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl and cyciobutenyl, and a non-limiting example of a bicycloalkenyl group is norbornenyl. Cycloalkyl, cycloalkenyl, bicycloalkyl, and bicycloalkenyl groups also include groups that are substituted with one or more oxo moieties. Examples of such groups with oxo moieties are oxocyclopentyl, oxocyclobuty!, oxocyclopentenyl, and norcamphoryl.
The term “aryl”, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, and fluorenyl.
The terms "heterocyclic", “heterocycloalky!l”, and like terms, as used herein, refer to non-aromatic cyclic groups containing one or more heteroatoms, prefereably from one to four heteroatoms, each selected from O, S and N. “Heterobicycloalkyl” groups are non-aromatic two- ringed cyclic groups, wherein said rings share one or two atoms, and wherein at least one of the rings contains a heteroatom (O, 8, or N). Heterobicycloalkyl groups for purposes of the present invention, and unless otherwise indicated, include spiro groups and fused ring groups. in one embadiment, each ring in the heterabicycloalkyl contains up to four heteroatoms (i.e. from zero to four heteroatoms, provided that at least one ring contains at least one heteroatom). The heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridiny}, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3- dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyt, quinoiizinyi, quinuclidinyl, 1,4-dioxaspirof4.5]decy!, 1,4-dioxaspiro[4.4Inonyl, 1,4- } dioxaspiro[4.3]octyl, and 1 ,4-dioxaspiro[4.2]heptyl. “Heteroaryl”, as used herein, refers to aromatic groups containing one or more ” heteroatoms (O, S, or N), preferably from one to four heteroatoms. A multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a “heteroaryl” group. The heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties. Examples of heteroaryl groups are pyridinyl,
pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyi, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, ’ isoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinoly!, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl, benzofuryl, furopyridinyl, pyralopyrimidinyi, and azaindalyl.
The foregoing groups, as derived from the compounds listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol- 1-y! (N-attached) or pyrrol-3-y! (C-attached). The terms referring to the groups also encompass all possible tautomers.
In one embodiment, this invention provides compounds of formula 1, wherein R? is -C(=O)NR°®- or -C(=0)(CR'R"),-. In another embodiment, R'® and R'! of -C(=0)(CR'°R"),- are at each iteration of n both hydrogen. In another embodiment, R® of ~C(=O)NR®- is hydrogen. in another embodiment, R® is -C(=O)NR®- or -C(=O)}(CR"R'"),- and R? is hydrogen. In another embodiment, R? is -(CR™R'"),-, and n is zero. In a preferred embodiment R® is -(CR'°R)-, nis zero, and R* is (C¢-C,)aryl or (5-14 membered) heteroaryl, each optionally substituted as recited above.
In another embodiment of the invention, a compound of formula 1 is provided wherein
R'is optionally substituted (C,Cg)cycloalkyl or optionally substituted (Cs-C,y) bicycloalkyl.
Preferred embodiments are wherein R' is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, each optionally substituted as recited above (i.e. optionally with from one to six substituents R® independently selected from F, Cl, Br, |, nitro, cyano, -CF,; -NR'RS -NR’C(=0)R?, -NR’C(=0)OR® -NR'C(=O)NR°R® -NR’S(=0),R?, -NR’S(=0),NRR®, -OR’, -OC(=0)R’, -OC(=0)OR’, -C(=0)OR’, -C(=0)R’, -C(=ONR'R?, -OC(=0Q)NR’R®, -OC(=0)SR’, -SR’, -8(=0)R’, -S(=0),R’, -S(=0),NR’R®, and R’). In a more preferred embodiment, R' is (C,-
Cs)oycloalkyl or optionally substituted (Cs-C,;) bicycloalkyl, for example cyclopropyl, cyclobutyt, cyclopentyl, cyclohexyl, or norbornyl, and is optionally substituted with from one to three substituents independently selected from F, Cl, Br, 1, nitro, cyano, -CF;, -NR'R®, -NR’C(=0O)R®, -OR’, -C(=0)OR’, -C(=O)R’, and R’. More preferably, R' is (C;-Cg)cycloalkyl or optionally = substituted (Cs-C,,) bicycloalkyl, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or norbornyl, and R' is substituted with -NR'C(=O)R®, (C,C,aryl, (3-8 membered) ~ heterocycloalkyl, or (5-14 membered) heteroaryl, and wherein said aryl, heterocycloalkyl, and heteroaryl are each optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, NO,, -CN, -CF; -NR"R", -NR"C(=O)R", -NR"C(=O)OR', -NR"°C(=0)NR"R", -NR"S(=0),R"", -NR"S(=0),NR''R"?, -OR", -OC(=0)R", -OC(=0)OR",
-OC(=0)NR™R", -OC(=0)SR™, -SR™ -S(=0)R™, -S(=0),R?, -S(=0),NRR", -C(=O)R", } -C(=0)OR", -C(=0O)NR™R", and R™. In another embodiment of the invention, R' is bicyclo- [3.1.0}-hexyl and is optionally substituted as recited above (i.e. optionally substituted with from ’ one to six substituents R® independently selected from F, Cl, Br, I, nitro, cyano, -CF,, -NR'R®, -NR'C(=0)R?, -NR'C(=0)OR®?, -NR’C(=O)NR®R®, -NR'S(=0),R?, -NR’S(=0),NR°R®, -OR’, -OC(=0)R’, -OC(=0)OR’, -C(=0)OR’, -C(=0)R’, -C(=O)NR’R®, -OC(=0)NR'R?, -OC(=0)SR’, -SR’, -S(=0)R’, -8(=0),R’, -S(=0),NR’R’, and R".
In another embodiment of the invention, a compound of formula 1 is provided wherein
R' is optionally substituted straight chain or branched (C.,-Cglalkyl or optionally substituted straight chain or branched (C,-Cg)alkenyl.
In another embodiment of the invention, compounds of formula 1 are provided, but wherein R? is hydrogen. In a further embodiment, R? is hydrogen, and R’ is as subdefined in the preceding paragraphs.
In another embodiment, this invention provides a compound of formula 1 wherein R* is (C-Cilaryl or (5-14 membered) heteroaryl, each optionally substituted. In a preferred embodiment, R* is optionally substituted phenyl or optionally substituted pyridyl. In another preferred embodiment, R* is naphthyl, quinolyl, or isoquinolyl, each optionally substituted. In another embodiment, R* is napthyl, quinolyl, or isoquinolyl, and is unsubstituted. In another embodiment, R* is pyrimidinyl, pyrazinyl, or pyridazyl, and in each case R* is optionally substituted. In a further embodiment, R* is pyrimidinyl, pyrazinyl, or pyridazyl, and R* is unsubstituted.
In another embodiment, compounds of formula 1 are provided, wherein R? is specifically hydrogen, and R* is as subdefined in the preceding paragraph.
Examples of preferred compounds of formula 1 are: (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yt)-N',N'-dimethyl-pyridine-2,6-diamine; (5-ethyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl}-amine; (5-cyclobuty!-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-2-yl-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-1-yl-amine;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-naphthalene-1,4-diamine;
N-{5-cyclobutyl-2H-pyrazol-3-y1)-N',N'-dimethyl-pyridine-2,6-diamine; : (5-cyclobutyl-2H-pyrazol-3-yl)-(6-trifluoromethyl-pyridin-2-yl}-amine; (3-benzyloxy-phenyi)-(5-cyclobutyl-2H-pyrazol-3-yl}-amine; (5-cyclobutyl-2H-pyrazol-3-yi)-(3-trifluoromethyl-phenyl)-amine,;
N-({5-cyclobutyl-2H-pyrazol-3-y)-N',N'-dimethyl-benzene-1,3-diamine;
(5-cyclobuty!-2H-pyrazol-3-yl)-(3-methoxy-phenyl}-amine; : {5-cyclobutyl-2H-pyrazol-3-yl}-(4-nitro-phenyl}-amine; (4-chloro-benzyl)-{5-cyclobutyl-2H-pyrazol-3-yl)-amine; : {3-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-y!}-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-quinolin-2-yl-amine; [5-(1,4-dioxa-spirof4.4}non-7-yl)-1H-pyrazol-3-yl}-(3-trifluoromethyl-phenyl)-amine; (6-chloro-pyridin-2-y!)-(5-cyclobutyl-2H-pyrazol-3-yi)-amine; 3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi]-cyclopentanone; (5-cyclobutyl-2H-pyrazol-3-y1})-(6-methoxy-4-methyl-quinolin-2-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-trifluoromethoxy-phenyl)-amine; (2-chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yi)-amine; 3-trans-[5-(3-trifluoromethyl-phenytamino)-2H-pyrazol-3-yl}-cyclopentanol; (3,5-bis-trifluoromethyl-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; [5-(3-cis-benzylamino-cyclopentyl}-1H-pyrazol-3-yil-(3-trifiuoromethyl-phenyi)-amine; {5-[3-cis-(4-methoxy-benzylamino)-cyclopentyl]-1H-pyrazol-3-yl}-(3-trifluoromethyl- phenyl)-amine; 4-(5-cyclobutyl-2H-pyrazol-3-ylamino)-benzonitrile; (5-cyclobutyl-2H-pyrazol-3-y!)-(3-fluoro-phenyl}-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3,5-dichloro-phenyi)-amine; (2-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yi)-amine;
N-{cis-3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi]-cyclopentyl}-acetamide; pyridin-2-yl-{3-trans-[5-(3-triflusromethyi-phenylamino)-2H-pyrazol-3-yl}-cyclopentyl}- amine; (5-cyclobutyl-1H-pyrazol-3-yl)-(4-methoxy-phenyl}-amine; pyridine-2-carboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-amide; 3-triffuoromethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-benzamide; : cyclobutanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi}- cyclopentyl}-amide; ’ 2,2-dimethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi}-cyclopentyl}- propionamide; - 4-fluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}- benzamide; 2,2,2-trifluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}-cyclopentyl}- acetamide;
cyclopropanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}- : cyclopentyl}-amide;
N-{3-[5-(3-trifluoromethyl-phenyiamino)-2H-pyrazol-3-yi}-cyclopentyl}-propionamide; : cyclohexanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}- cyclopentyl}-amide;
N-[5-(3-acetylamino-cyclopentyl)-2H-pyrazol-3-yi}-2-naphthalen-1-yl-acetamide; cyclopropanecarboxylic acid {3-[5-(2-naphthalen-1-yl-acetylamino)-1H-pyrazol-3-yl}- cyclopentyl}-amide; 2-naphthalen-1-yl-N-{5-[3-(2,2,2-trifluoro-acetylamino)-cyclopentyl}-2H-pyrazol-3-yl}- acetamide;
N-{3-[5-(2-naphthalen-1-yl-acetylamino)-1H-pyrazol-3-yl}-cyclopentyl}-benzamide;
N-(5-hydroxymethy!-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide; 2-naphthalen-1-yl-N-[5-{thiazol-2-ylaminomethyl)-1H-pyrazol-3-yi]-acetamide;
N-[5-((1S)-hydroxy-ethyl}-2H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide;
N-{5-[(18)-(benzooxazol-2-yloxy)-ethyl]-1H-pyrazol-3-yl}-2-naphthalen-~1-yl- acetamide;
N-{5-[(1S)-(benzothiazol-2-yloxy)-ethyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
N-[5-(3-hydroxy-1-methyl-propyl}-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide;
N-[5-(benzothiazol-2-yloxymethyl)-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide;
N-{5-[3-(benzothiazol-2-yloxy)-1-methyi-propyll-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide;
N-[5-(2-hydroxy-(1S)-methyl-ethyl}-2H-pyrazol-3-yi]-2-naphthalen-1-yl-acetamide;
N-{5-[(1R)-(benzothiazol-2-yloxy)-ethyl}-1H-pyrazol-3-yl}-2-naphthalen-1-y}- acetamide;
N-[5-(3-acetylamino-1-methyl-propyl)-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide; 3-methoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}-cyciobutyl}- benzamide;
N-[5-(cis-3-acetylamino-cyciobutyl)-1H-pyrazol-3-yl]-2-naphthalen-1-yi-acetamide;
N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yi}-cyclobutyl}-benzamide; : 2-cyclopropyl-N-{¢cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazel-3-yl}- cyclobutyl}-acetamide; - 6-chloro-pyridine-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yi}-cyclobutyi}-amide; quinoline-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- cyclobutyl}-amide;
pyrazine-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- ‘ cyclobutyl}-amide; 4-methoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}-cyclobutyl}- : benzamide;
N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yi]-cyciobutyl}-3-nitro- benzamide;
N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-ylj-cyclobutyl}-3- trifftucromethyl-benzamide;
N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}-cyclobutyl}- isobutyramide; 2-phenyl-cyclopropanecarboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl]-cyciobutyl}-amide;
N-{5-[cis-3-(benzoaxazol-2-yloxy)-cyclobutyl}-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; 4-dimethylamino-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- cyclobutyl}-benzamide; 3,5-dimethoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- cyclobutyi}-benzamide; 2-naphthalen-1-y!-N-[5-(cis-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl}-acetamide;
N-{5-[cis-3-(3-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yi}-2-naphthalen-1-yi- acetamide;
N-{5-[cis-3-(2-methoxy-phenyl}-cyclobutyl]-2H-pyrazol-3-yI}-2-naphthalen-1-yl- acetamide;
N-{5-[cis-3-(4-methoxy-phenyl}-cyclobutyl]-2H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1-yl-N-[5-(cis-3-p-tolyl-cyclobutyl)-2H-pyrazal-3-yl}-acetamide;
N-{5-[cis-3-(4-chioro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; 2-(4-methoxy-phenyl)-N-{5-[cis-3-(2-methoxy-phenyl)-cyciobutyl]-2H-pyrazol-3-yl}- acetamide; : N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[cis-3-(2-methoxy-phenyl}-cyclobutyl]-2H-pyrazol-3-yl}-2-phenyl-acetamide; : N-{5-{cis-3-(2-methoxy-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-pyridin-3-yi-acetamide;
N-{5-[cis-3-(4-methoxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; 2-quinolin-6-yI-N-[5-(cis-3-p-tolyl-cyclobutyl)-1H-pyrazol-3-yl}-acetamide;
N-{5-[cis-3-(4-fluoro-phenyl)-cyclobutyl]-1H-pyrazol-3-yi}-2-quinolin-6-yl-acetamide;
N-{5-[cis-3-(4-chloro-phenyl)-cyclobutyl]-1H-pyrazol-3-yi}-2-quinolin-6-yl-acetamide; ' 2-quinolin-6-yl-N-[5-(cis-3-m-tolyl-cyclobutyl)-1H-pyrazol-3-yl}-acetamide; 4-dimethylamino-N-{cis-3-[5-(2-naphthalen-1-yi-acetylamino)-2H-pyrazol-3-yl]- : cyclobutyl}-benzamide; 2-naphthalen-1-yI-N-{5-[cis-3-(pyridin-2-yloxy)-cyciobutyl}-1H-pyrazol-3-yl}-acetamide; 6-methyl-pyridine-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl]-cyclobutyl}-amide; 2-phenyl-cyclopropanecarboxylic acid methyi-{cis-3-[5-(2-naphthalen-1-yl- acetylamino)-2H-pyrazol-3-yl}-cyclobutyl}-amide;
N-{5-[cis-3-(3-methyl-pyrazin-2-yloxy)-cyclobutyl}-1H-pyrazol-3-yli}-2-naphthalen-1-yl- acetamide; {5-{cis-3-(2-methoxy-phenyl)-cyclobutyl]- 1H-pyrazol-3-yl}-(6-methoxy-pyridin-2-yl)- amine;
N-{5-[cis-3-(3,6-dimethyl-pyrazin-2-yloxy)-cyciobutyl}-1H-pyrazol-3-yi}-2-naphthalen- 1t-yl-acetamide;
N-{5-[cis-3-(3-methoxy-pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1- yl-acetamide; 2-methyi-cyclopropanecarboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl}-cyclobutyl}-amide; 2-naphthalen-1-y}-N-{5-[cis-3~-(3-trifluoromethyl-pyridin-2-yloxy)-cyclobutyl]-1H- pyrazol-3-yl}-acetamide; ’ 2-naphthalen-1-yl-N-{6-[cis-3-(3-nitro-pyridin-2-yloxy)-cyclobutyl]- ~~ 1H-pyrazol-3-yl}- acetamide;
N-{5-[cis-3-(benzothiazol-2-yloxy)-cyciobutyl]-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1-yl-N-{5-[cis-3-(4-triflucromethyl-pyrimidin-2-yloxy)- cyclobutyl}-1H- pyrazol-3-yl}-acetamide; 2-naphthalen-1-yl-N-{5-[3-(5-nitro-pyridin-2-yloxy)-cyclobutyl]- 1H-pyrazol-3-yl}- acetamide; 2-naphthalen-1-yl-N-{5-[3-(pyrimidin-2-yloxy)-cyclobutyl}-1H-pyrazoi-3-yl}-acetamide; : 2-naphthalen-1-yi-N-{5-[3-(5-triflucromethyl-pyridin-2-yloxy)- cyclobutyl]-1H-pyrazol-3- yl}-acetamide; : N-{5-[3-(6-methoxy-pyridazin-3-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1-yl-N-{5-[3-(pyrazin-2-yloxy)-cyclobutyl}-1H-pyrazol-3-yi}-acetamide;
N-{5-[3-(6-methyl-pyridin-2-yloxy)-cyclobuty!}-1H-pyrazol-3-yl}-2-naphthalen-1-yl- : acetamide;
N-{5-[3-(6-chloro-benzothiazol-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthaien-1- ’ yl-acetamide;
N-{5-[3-(6-methoxy-benzothiazol-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yi}-2-naphthalen- 1-yl-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other examples of preferred compounds of formula 1 are:
N-{5-[cis-3-(4-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide;
N-{5-[cis-3-(3-Hydroxy-phenyl)-cyclobutyl]-1 H-pyrazol-3-yi}-2-quinolin-6-yl-acetamide; 2-Naphthalen-1-yI-N-[5-(cis-3-pyridin-3-yl-cyclobutyl)-2H-pyrazol-3-yi}-acetamide;
N-[5-(cis-3-Naphthalen-2-yi-cyciobutyl)-2H-pyrazol-3-yl}-2-pyridin-3-yl-acetamide;
N-(5-Indan-2-yl-1H-pyrazol-3-yl)-2-quinolin-6-yl-acetamide;
N-[5-(cis-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-[5-(cis-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide; 2-(4-Methoxy-phenyl)-N-[5-(cis-3-pyridin-4-yl-cyclobutyl)-2H-pyrazol-3-yl}-acetamide;
N-{5-[3-(cis-2-Dimethylaminomethyl-phenyl)-cyclobutyt]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide;
N-(5-{cis-3-[3-(2-Dimethylamino-ethoxy)-phenyl}-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide;
N-{5-{cis-3-(2-Hydroxy-phenyl)-cyclobutyl]-2H-pyrazal-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-(5-{cis-3-[2-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yi})-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-[5-(cis-3-phenyi-cyciobutyl)-2H-pyrazol-3-yl]-acetamide;
N-{5-[cis-3-(2-Fluaro-phenyl)-cyclobutyi]-2H-pyrazol-3-yi}-2-{4-methoxy-phenyl)- acetamide;
N-(5-{cis-3-[4-(Azetidin-3-yloxy)-phenyl]-cyclobutyl}-2H-pyrazoi-3-yl)-2-(4-methoxy- phenyl)-acetamide;
N-(5-{cis-3-[2-(Azetidin-3-yloxy)}-phenyl]-cyclobutyl}-2H-pyrazol-3-yi)-2-(4-methoxy- - phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[cis-3-(2-methylsulfanyl-phenyl)-cyclobutyl}-2H-pyrazol-3- ’ yl}-acetamide;
N-{5-[cis-3-(2-Amino-phenyl)-cyclobutyl}-2H-pyrazol-3-yi}-2-(4-methoxy-phenyi)- acetamide;
N-{5-{cis-3-(4-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yi}-2-(4-methoxy-phenyl})- ) acetamide;
N-{5-[cis-3-(2-Cyana-phenyl)-3-hydroxy-cyclobutyl]-2H-pyrazol-3-yi}-2-(4-methoxy- : phenyl)-acetamide;
N-{5-[cis-3-(2-Hydroxy-ethyl)-cyclobutyl]-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide;
N-{5-[cis-3-(3-Cyano-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[cis-3-(2-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yi}-2-(4-methoxy-phenyl)- acetamide;
N-{5-[cis-3-(3-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; 4-(cis-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester;
N-{5-[cis-3-(4-Hydroxymethyl-phenyl}-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[cis-3-(2-Hydroxy-pheny!)-cyclobutyl]-1H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-{cis-3-(2-Hydroxy-phenyl}-cyclobutyl]- 1 H-pyrazol-3-yl}-2-quinolin-6-yi-acetamide;
N-{5-[cis-3-(2-Hydroxy-phenyl)-cyciobutyl]-1H-pyrazol-3-yl}-acetamide;
Cyclopropanecarboxylic acid {5-[cis-3-(2-hydroxy-phenyl)-cyclobutyl}-1H-pyrazol-3- yl}-amide;
N-{5-[cfs-3-(2-Hydroxy-phenyl)-cyclobutyl}-1H-pyrazol-3-yl}-isobutyramide;
N-{5-[cis-3-(3-Aminomethyl-phenyl}-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide;
N-{5-[cis-3-(3-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 3-(cis-3-{5-[2-(4-Methoxy-phenyi}-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl! ester;
N-{5-[cis-3-(3-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-{4-methoxy- phenyl)-acetamide; ’ N-(5-{cis-3-[3-(1-Hydroxy-1-methyl-ethyl)-phenyl]-cyciobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyt)-acetamide; : N-{5-[cis-3-(3-Ethylaminomethyl-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl}-acetamide;
N-{5-[cis-3-(3-Cyclobutylaminomethyl-phenyl)-cyclobutyi]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; :
2-(4-Methoxy-phenyl)-N-{5-[cis-3-(3-propylaminomethyl-phenyl)-cyclobutyl}-2H- ‘ pyrazol-3-yl}-acetamide;
N-{5-{cis-3-(3-Cyclopentylaminomethyl-phenyl)-cyclobutyl}-2H-pyrazol-3-yi}-2-(4- : methoxy-phenyl)-acetamide;
N-(5-{cis-3-[3-(Benzylamino-methyl)-phenyl]-cyciobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl}-N-{5-[3-(3-methylaminomethyl-phenyl}-cyclobutyl}-2H-pyrazoi- 3-yl}-acetamide;
N-{5-[cis-3-(3-Cyclopropylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-y(}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[cis-3-(3-pyrrolidin-1-yimethyl-phenyl)-cyclobutyl}-2H- pyrazol-3-yl}-acetamide;
N-{5-{cis-3-(3-Diethylaminomethyl-phenyl}-cyclobutyl]-2H-pyrazal-3-yi}-2-(4-methaxy- phenyl)-acetamide;
N-{5-[cis-3-(3-Azetidin-1-ylmethyl-phenyl}-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other specific examples of compounds of the invention of formula 1 are:
N-[5-(cis-3-pyridin-2-yl-cyclobutyl)-1H-pyrazol-3-yl]-2-quinolin-6-yl-acetamide;
N-{5-(cis-3-pyridin-3-yl-cyclobutyl})-1H-pyrazol-3-yi]-2-quinolin-6-yl-acetamide;
N-{5-(cis-3-pyridin-4-yl-cyclobutyl}-1H-pyrazol-3-yi}-2-quinolin-6-yl-acetamide; :
N-{5-(cis-3-pyrazin-2-yl-cyclobutyl)- 1 H-pyrazol-3-yil-2-quinalin-6-yl-acetamide;
N-[5-(cis-3-pyrimidin-4-yl-cyclobuty!)-1H-pyrazol-3-yi}-2-quinolin-6-yl-acetamide;
N-{5-[cis-3-(3-methoxy-pyridin-2-yl)-cyclobutyi]-1H-pyrazol-3-yl}-2-quinolin-6-yi- acetamide;
N-{5-[cis-3-(4-methoxy-pyridin-3-yl}-cyclobutyl]-1H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[cis-3-(3-methoxy-pyridin-4-yl)-cyclobutyl}-1 H-pyrazol-3-yl}-2-quinolin-6-yl- acetamide;
N-{5-[cis-3-(2-methoxy-pyridin-3-yl)-cyclobutyl}- 1 H-pyrazol-3-yl}-2-quinolin-6-yl- ’ acetamide;
N-{5-[cis-3-(5-methoxy-pyrimidin-4-yl)-cyclobutyl}-1H-pyrazol-3-yl}-2-quinolin-6-yl- : acetamide;
N-{5-[cis-3-(1-ethyl-1H-imidazol-2-yl)-cyclobutyl}-1H-pyrazol-3-yi}-2-quinolin-6-yi- acetamide;
N-{5-[cis-3-(1-ethyl-1H-pyrrol-2-yl}-cyclobutyl]- 1H-pyrazol-3-yl}-2-quinalin-6-yi- ‘ acetamide;
N-{5-[cis-3-(2-aminomethyl-phenyl}-cyclobutyi]- 1H-pyrazal-3-yl}-2-quinalin-6-yi- : acetamide;
N-{5-[cis-3-(2-pyrrolidin-1-ylmethyl-phenyl)-cyciobutyl}- 1 H-pyrazol-3-yl}-2-quinolin-6- yi-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
Other specific examples of compounds of formula 1 are: {4-[(5-cyclobutyl-1H-pyrazol-3-ylcarbamoyl)-methyl]-phenyl}-acetic acid;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(1H-indol-3-yl)-acetamide; 2-(3-chloro-phenyl)-N-(5-cyclobutyl-1H-pyrazol-3-yl)-acetamide; 2-(3-bromo-phenyl)-N-(5-cyclobutyl-1H-pyrazol-3-yt)-acetamide; 2-biphenyl-4-yl-N-(5-cyclobutyl-1H-pyrazol-3-yl)-acetamide; 2-biphenyl-4-yl-N-(5-cyclobutyl-1H-pyrazol-3-yl}-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-y1)-2-(3,4,5-trimethoxy-phenyi)-acetamide; {2-[(5-cyclobutyl-1H-pyrazol-3-ylcarbamoyl)-methyl]-phenyl}-acetic acid;
N-(5-cyclobutyl-1H-pyrazol-3-y})-2-(3,4-dichloro-phenyl)-acetamide; 2-(2-chloro-phenyl)-N-(5-cyclobutyl-1H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(2-fluoro-phenyl)-acetamide; 2-(4-butoxy-phenyl)-N-(5-cyclobutyl-1H-pyrazol-3-yl}-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(2,4-difluoro-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl}-2-(2-iodo-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(2,3-dimethoxy-phenyf)-acetamide;
N-{5-cyclobutyl-1H-pyrazol-3-y1)-2-(2,5-dihydroxy-phenyl)-acetamide;
N-(5-cyclobutyi-1H-pyrazol-3-yl)-2-(3-hydroxy-4-methoxy-phenyl)-acetamide; 2-(4-acetylamino-phenyl)-N-(5-cyclobutyl-1H-pyrazol-3-yl}-acetamide;
N-(5-cyclobuty!-1H-pyrazol-3-yl}-2-(4-trifluoromethyl-phenyl)-acetamide; 2-(4-chloro-3-nitra-phenyl}-N-(5-cyclobutyi- 1H-pyrazol-3-yl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-hydroxy-3,5-dinitro-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl})-2-(3,4-difluoro-phenyl)-acetamide; ) 2-(2,4-bis-triflucromethyi-phenyl)-N-(5-cycliobutyl-1H-pyrazol-3-yt)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(3,5-difluoro-phenyl)-acetamide; : N-(5-cyclobutyl-1H-pyrazol-3-yl}-2-(2-fluoro-3-trifluoromethyl-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-fluoro-3-trifiuoromethyl-phenyl}-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl}-2-(2 4,6-trifluoro-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-methylsulfanyl-phenyl!)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(3-hydroxy-phenyl)-acetamide; : N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl-acetamide; 2-(4-chloro-phenyl)-N-(5-cyclopentyl-2H-pyrazol-3-yl)-acetamide; ) N-(5-cyclopentyi-1H-pyrazoi-3-yl)-2-naphthalen-2-yl-acetamide;
N-(5-cyclobutyl-2H-pyrazol-3-yl)-2-(2,4-dichloro-phenyl)-acetamide;
N-(5-cyclobutyl-2H-pyrazol-3-yi)-2-quinolin-6-yi-acetamide; 2-(3-amino-phenyl)-N-(5-cyclobutyl-2H-pyrazol-3-yi)-acetamide; 1-(5-cyclobutyl-1H-pyrazol-3-yl)-3-naphthalen-1-yl-urea;
N-(5-cyclohexyl-1H-pyrazol-3-yl)-2-naphthalen-2-yl-acetamide;
N-(5-cyciohexyl-1H-pyrazol-3-yi)-2-phenyl-acetamide; 2-(4-chloro-phenyl)-N-(5-cyclohexyl-1H-pyrazol-3-yl}-acetamide; :
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-phenoxy-phenyl)-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl)-2-(4-dimethylamino-phenyl)-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-(2,3,4-frimethoxy-phenyl}-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-(4-isopropyl-pheny!)-acetamide;
N-(5-cyclopentyl-2H-pyrazol-3-yl)-2-pyrrolo[2,3-b]pyridin-1-yl-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-yl}-2-m-tolyl-acetamide;
N-(5-~cyclopentyl-2H-pyrazol-3-yi)-2-p-tolyl-acetamide;
N-(5-cyclobutyl-1H-pyrazol-3-y!)-2-(3-trifluoromethoxy-phenyl)-acetamide,
N-[5-(3-benzyloxy-propyl}-1H-pyrazol-3-yi]-2-naphthalen-2-yl-acetamide; 4-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol-3-yl}-piperidine-1-carboxylic acid benzyl ester; 2-naphthalen-2-yl-N-(5-piperidin-4-yl-2H-pyrazol-3-yl)-acetamide;
N-[5-(1-acetyl-piperidin-4-yl)-2H-pyrazol-3-yl}-2-naphthalen-2-yl-acetamide; :
N-[5-(1-benzoyl-piperidin-4-yl)-2H-pyrazol-3-vl}-2-naphthalen-2-yl-acetamide; 4-{5-(2-naphthalen-1-yl-acetylamino)-1H-pyrazol-3-yl]-piperidine-1-carboxylic acid benzyl ester;
N-[5-(1-cyclobutanecarbonyl-piperidin-4-yl)-2H-pyrazol-3-yl}-2-naphthalen-2-yl- acetamide;
N-{3-[5-(2-naphthalen-2-yl-acetylamino)-4H-pyrazol-3-ylj-propyl}-benzamide; : ’ N-{3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yi]-propyl}-benzamide;
N-{5-[1-(3-methyl-butyl)-piperidin-4-yI}-1H-pyrazol-3-yl}-2-naphthalen-2-yl-acetamide; : N-[3-(5-phenylacetylamino-2H-pyrazol-3-yl)-propyl}-benzamide;
N-{3-[5-(2-m-tolyl-acetylamino)-2H-pyrazol-3-yi]-propyl}-benzamide;
N-(3-{5-[2-(3-chloro-phenyl)-acetylamino]-2H-pyrazol-3-yl}-propyl)-benzamide;
6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol- ’ 3-yl]-cyciobutyl}-amide; 6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol- ‘ 3-yl}-cyclobutyl}-amide; 6-methyl-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol- 3-yl}-cyclobutyl}-amide;
N-{5-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-cyclobutyl}-2H-pyrazol-3-yi}-2- naphthalen-2-yi-acetamide; 6-chloro-pyridine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol- 3-yll-cyclobutyl}-amide;
N-{3-[5-(2-naphthalen-2-yl-acetylamino}-1H-pyrazol-3-yl]-cyclobutyl}-benzamide; 2-naphthalen-2-yl-N-[5-(2-pyridin-2-yi-ethyl}-2H-pyrazol-3-yl}-acetamide; 2-naphthalen-2-yl-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl]-acetamide; 2-naphthalen-2-yl-N-[5-(2-pyridin-4-yl-ethyl)}-2H-pyrazol-3-yi}-acetamide; 2-naphthalen-1-yI-N-[5-(2-pyridin-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide; 2-naphthalen-1-yl-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl}-acetamide; 2-naphthalen-1-yl-N-{5-(2-pyridin-4-yl-ethy!)-2H-pyrazol-3-yl}-acetamide; 2-(3-methoxy-pheny)-N-[5-(2-pyridin-2-yl-ethyl)-2H-pyrazol-3-yli}-acetamide; 2-(3-methoxy-phenyl)-N-[5-(2-pyridin-3-yl-ethyl)-2H-pyrazol-3-yl}-acetamide, 2-(3-methoxy-phenyl)-N-[5-(2-pyridin-4-yi-ethyl)-2H-pyrazol-3-yi]-acetamide; 2-(3-methoxy-phenyl)-N-[5-(2-thiazol-2-yl-ethyl)-2H-pyrazol-3-yl]-acetamide; 2-naphthalen-1-yl-N-[5-(2-thiazol-2-yl-ethy!}-2H-pyrazol-3-yl}-acetamide; 2-naphthalen-2-yi-N-[5-(2-thiazol-2-yl-ethyl)-2H-pyrazol-3-yi]-acetamide;
N-[5-(1-benzyl-piperidin-4-yl)-1H-pyrazol-3-yl]-2-naphthalen-2-yl-acetamide; 2-naphthalen-1-yl-N-(5-piperidin-4-yl-1H-pyrazol-3-yl)-acetamide; 2-(4-chloro-phenyl}-N-{3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazol-3-yl}- cyclobutyl}-acetamide; pyrazine-2-carboxylic acid {3-[5-(2-naphthalen-2-yl-acetylamino)-1H-pyrazoi-3-yIl- cyclobutyl}-amide; 2-(3-methoxy-pheny!)-N-{5-[2-(2-trifluoromethyl-phenyi)-ethyl]-2H-pyrazol-3-yl}- ) acetamide; 2-(3-methoxy-phenyl)-N-{5-[2-(3-trifluoromethyl-phenyl)-ethyl)-2H-pyrazol-3-yl}- : acetamide; 2-(3-methoxy-phenyl)-N-{5-[2-(4-trifluoromethyl-phenyl)-ethyl]-2H-pyrazol-3-yi}- acetamide; )
B-methyl-pyridine-2-carboxylic acid (3-{5-{2-(3-methoxy-phenyl)-acetylamino}-2H- ’ pyrazol-3-yl}-cyclobutyl}-amide; 6-methyl-pyridine-2-carboxylic acid (3-{5-[2-(4-methoxy-phenyl)-acetylamino]-2H- ‘ pyrazol-3-yl}-cyclobutyl)-amide; 6-methyl-pyridine-2-carboxylic acid (3-{5-[2-(4-chloro-phenyl)-acetylamino]-2H- pyrazol-3-yi}-cyclobutyl)-amide; and pharmaceutically acceptable salts of said compounds.
Salts of compounds of formula 1 can be obtained by forming salts with any acidic or basic group present on a compound of formula 1. Examples of pharmaceutically acceptable salts of the compounds of formula 1 are the salts of hydrochloric acid, p-toluenesulfonic acid, fumaric acid, citric acid, succinic acid, salicylic acid, oxalic acid, hydrobromic acid, phosphoric acid, methanesulfonic acid, tartaric acid, maleic acid, di-p-toluoyl tartaric acid, acetic acid, sulfuric acid, hydroiodic acid, mandelic acid, sodium, potassium, magnesium, calcium, and lithium.
The compounds of formula 1 may have optical centers and therefore may occur in different enantiomeric and other sterecisomeric configurations. The invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of formula 1, as well as racemic and other mixtures thereof.
The subject invention also includes isotopically-labeled compounds, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3H, 'C, C, ®F, '®} and '®I. Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. lsotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as *H and **C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., *H, and carbon-14, i.e., "*C, isotopes are particularly preferred for their ease of preparation and detectability. ''C and '®F isotopes are ) particularly useful in PET (positron emission tomography), and '#| isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain ; imaging. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula 1 of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the ' Examples below, by substituting a readily available isotopically labeled reagent for a non- isotopically labeled reagent. ' This invention also includes compounds of the formula
NN Prot
Ve o NH,
Rr?
O— ; wherein Prot is a protecting group;
R?is H, F, -CH,, -CN, or -C(=0)OR’; and n is an integer selected from 1, 2, 3, and 4. } Compounds of formula 1 are useful as intermediates for synthesizing certain compounds of formula 1 that are described herein.
Preferably, nis 1.
Examples of specific protecting groups include, but are not limited to t-butyl and -CH,-
Ar, wherein “Ar” is an aryl or heteroaryl group. An example of the latter type of protecting group is para-methoxybenzyl.
This invention also provides a pharmaceutical composition for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective in inhibiting abnormal celi growth, and a pharmaceutically acceptable carrier.
This invention also provides a pharmaceutical composition for treating a disease ar condition comprising abnormal cell growth in a mammal, including a human, comprising a compound of formula 1 in an amount effective to inhibit cdk2 activity, and a pharmaceutically acceptable carrier.
This invention also provides a method for treating a disease or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the mammal a compound of formula 1 in an amount effective in inhibiting abnormal cell growth. ) This invention also provides a method for treating a diseases or condition comprising abnormal cell growth in a mammal, including a human, comprising administering to the ) mammal a compound of formula 1 in an amount effective to inhibit cdk2 activity. in a pharmaceutical composition or method of this invention for treating a disease or condition comprising abnormal cell growth, the disease or condition comprising abnormal cell growth is in one embodiment cancer. The cancer may be a carcinoma, for example carcinoma

Claims (14)

CLAIMS What is claimed is:
1. A compound of the formuia
H
A. H R' AI R? 1 wherein R' is a straight chain or branched (C,-Cy)alkyl, a straight chain or branched (C,- Cg)alkenyl, a straight chain or branched (C,-Cg)alkynyl, (C5-Cg)cycloalkyl, (C,-Cglcycloalkenyl, (3- 8 membered) heterocycloalkyl, (Cs-C,;)bicycloalkyl, (C,-C,;)bicycloalkenyl, or (5-11 membered) heterobicycloalkyl, and wherein R' is optionally substituted with from one to six substituents R® independently selected from F, Cl, Br, I, nitro, cyano, -CF, -NR'R® -NR’C(=O)R®, - -- 10 NRIC{(=0O)OR? -NR'C(=O)NR®R®?, -NR’S(=0),R%, -NR’S(=0),NR°R°, -OR’, -OC(=O)R’, - ~~ ~~ OC(=0)OR?, -C(=O)OR?, -C(=0)R’, -C(=O)NR'R®, -OC(=O)NR'R®, -OC(=O)SR’, -SR’, - S(=0)R’, -S(=0),R’, -S(=0),NR'R®, and R; R?is H, F, -CH,, -CN, or -C(=O)OR’; R¥is -C(=O)NR?-, -C(=0)0O-, -C(=0)(CR"R"),-, or (CRR""),-; R* is a straight chain or a branched (C,-Cg)alkyl, a straight chain or a branched (C,- Cglalkenyl, a straight chain or branched (C.-C; alkynyl), (C5-Cg)cycloalkyl, (C,-Cg)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,,)bicycloalkyl, (C,-C;,)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C4-C,4)aryl, or (5-14 membered) heteroaryl; and wherein R* is optionally substituted with from one to three substitutents R® independently selected from F, Ct, Br, 1, nitro, cyano, -CF; -NR'R® -NR'C(=O)R?, -NR’C(=0)OR®, -NR'C(=0)NR®R®, -NR’S(=0),R®, - NR’S(=0),NRPR®, -OR’, -OC(=O)R’, -OC(=0)OR’, -C(=0)OR’, -C(=O)R’, -C(=O)NR'R®, - OC(=O)NR'R®, -OC(=0)SR’, -SR’, -8(=0)R, -S(=0),R’, -S(=0),NR'R?, or R’; each R’, R%, and R® is independently selected from H, straight chain or branched (C,- Cs)alkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cg alkynyl), (Cs-Cy)cycloalkyl, (C,-Cgcycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,;)bicycloalkyl, ] (C;-Cyq)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C¢-C,)aryl, and (5-14 membered) heteroaryl, wherein R’, R®, and R® are each independently optionally substituted with from one to ) six substituents independently selected from F, CI, Br, I, -NO,, -CN, -CF,; -NR'"R" . NR'"C(=O)R", -NR'"C(=O)OR", -NR"C(=O)NR"'R™, -NR'*S(=0),R", -NR"S(=0),NR"'R®2, . OR", -OC(=0)R", -OC(=O)OR', -OC(=O)NR™R'", -OC(=0)SR", -SR™, -S(=0)R", -S(=0),R™ -S(=0),NR"R", -C(=0)R"?, -C(=0)OR'", -C{(=0)NR"R"", and RY;
or, when R” and R® are as in NR’R®, they may instead optionally be connected to form with the nitrogen of NR'R® to which they are attached a heterocycloalkyl moiety of from three to seven ring members, said heterocycloalkyl moiety optionally comprising one or two further ) heteroatoms independently selected from N, O, and S; each R'°, R", and R" is independently selected from H, straight chain or branched (C- Ce)alkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cq alkynyl), (C5-Cp)eycloalkyl, (C,-Cg)cycloalkenyl, (3-8 membered) heteracycloalkyt, (Cs-C,;)bicycloalkyl, (C,-Cy,)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (Ce-Cy4)aryl, and (5-14 membered) heteroaryl, wherein R'™, R"', and R™ are each independently optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, NO, -CN, -CF; -NR"R™, -NR®C(=O)R™, -NR™“C(=0)OR", -NR’C(=O)NR"R', -NR%S(=0),R", -NR"S(=0),NR"R", -OR™, -OC(=0)R®, -OC(=0)OR®, -OC(=O)NR®RY, -OC(=0)SR®, -SR™, -S(=O)R", -S(=0),R™, -S(=0),NR"R", -C(=0)R", -C(=0)OR™, -C(=0)NR™R™, and R", each R%, R", and R" js independently selected from H, straight chain or branched (C,- - -- - Cglalkyl, straight chain or branched (C,-Cg)alkenyl, straight chain or branched (C,-Cg alkynyl), (C5-Cg)eycloalkyl, (C,-Cy)cycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-Cy;)bicycloalkyl, (C,-C,,)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (C¢-Cy,)aryl, and (5-14 membered) heteroaryl, wherein R™, R', and R' are each independently optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, NO, -CN, -CF,, -NR"R", -NR'"C(=0)R", -NR'™C(=0)OR", -NR*C(=O)NR"R, -NR"S(=0),R"”, -NR'*S(=0),NR''R' -OR', .OC(=0)R'®, -OC(=0)OR'™, -OC(=O)NR'R', -OC(=O)SR', -SR'®, -S(=O)R', -5(=0),R'®, -8(=0),NR"™R" -C(=0)R", -C(=0)OR’, -C(=O)NR"R", and R™ each R*, R", and R" js independently selected from H, straight chain or branched (C,- Cplalkyl, straight chain or branched (C.,-Cglalkenyl, straight chain or branched (C,-C4 alkynyl), (Cs-Cg)cycloalkyl, (C,-Cgcycloalkenyl, (3-8 membered) heterocycloalkyl, (Cs-C,,)bicycloalkyl, (C;-C,4)bicycloalkenyl, (5-11 membered) heterobicycloalkyl, (CC, aryl, and (5-14 membered) heteroaryt; nis 0, 1,2, or 3; wherein R'* and R" in -C(=0)(CR"™R"),- and -(CR'R"),- are for each iteration of n defined independently as recited above; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R® is -(CR"R")_, ) -C(=O)NH- or -C(=O)(CR'"R"),-.
3. A compound according to claim 1, wherein R' is optionally substituted (C;-Cg)cycloalkyt or optionally substituted (Cs-C,,) bicycloalkyl.
:
4. A compound according to claim 3, wherein R' is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, or bicyclo-[3.1.0]-hexyl, each optionally substituted.
’ 5. A compound according to claim 1, wherein R' is optionally substituted straight chain or branched (C,-Cg)alky! or optionally substituted straight chain or branched (C,- Caglalkenyl.
6. A compound according to claim 1, wherein R* is (C.-C, )aryl or (5-14 membered) heteroaryl, each optionally substituted.
7. A compound according to claim 6, wherein R* is phenyl, pyridyl, naphthyl, quinolyl, isoquinolyl, pyrimidinyl, pyrazinyl, or pyridazyl, each optionally substituted.
8 A compound according to any of claims 1-7, wherein RZ is hydrogen.
9. A compound of claim 1, selected from the group consisting of: (5-ethyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-pyridin-2-yi)-amine Ce eee oo 15 (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-2-yl-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-naphthalen-1-yl-amine; N-(5-cyclobutyl-2H-pyrazol-3-yI)-N',N'-dimethyl-naphthalene-1,4-diamine; N-(5-cyclobutyl-2H-pyrazol-3-y)-N',N'-dimethyl-pyridine-2,6-diamine; (5-cyclobutyl-2H-pyrazol-3-yl}-(8-trifluoromethyl-pyridin-2-yl)-amine; (3-benzyloxy-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-triftuoromethyl-phenyl)-amine; N-(5-cyclobutyl-2H-pyrazol-3-yl)-N',N'-dimethyl-benzene-1,3-diamine; (5-cyclobutyl-2H-pyrazol-3-yl)-(3-methoxy-phenyi)-amine; (5-cyclobutyl-2H-pyrazol-3-yl)-(4-nitro-phenyl)-amine; (4-chloro-benzyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; (3-bromo-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yi)-quinolin-2-yl-amine; {5-(1,4-dioxa-spirof4.4]non-7-yl)-1H-pyrazol-3-yi]-(3-trifluoromethyl-phenyl}-amine; (6-chloro-pyridin-2-yl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; 3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazoi-3-yl]-cyclopentanone; ’ (5-cyclobutyl-2H-pyrazol-3-yl)-(6-methoxy-4-methyl-quinolin-2-yl)-amine; (5-cyclobutyl-2H-pyrazol-3-yi)-(3-trifluoromethoxy-phenyl)-amine; B (2-chloro-4-nitro-phenyl)-(5-cyclobutyl-2H-pyrazol-3-yl)-amine; 3-trans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentanol; (3,5-bis-trifluoromethyl-phenyl}-(5-cyclobutyl-2H-pyrazol-3-yl}-amine; [5-(3-cis-benzylamino-cyclopentyl)-1H-pyrazol-3-yi}-(3-trifluoromethyl-phenyl)-amine;
{5-[3-cis-(4-methoxy-benzylamino)-cyclopentyll-1H-pyrazol-3-yi}-(3-trifluoromethyl- phenyl)-amine; 4-(5-cyclobutyl-2H-pyrazol-3-ylamino)-benzonitrile; ) (5-cyclobutyl-2H-pyrazol-3-yl)-(3-fluoro-phenyl)-amine;
(5-cyclobutyl-2H-pyrazol-3-yh-(3,5-dichloro-phenyl)-amine; (2-broma-pheny!)-(5-cyclobutyl-2H-pyrazol-3-yi}-amine; N-{cis-3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}-cyclopentyl}-acetamide; pyridin-2-yl-{3-trans-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]-cyclopentyl}-
amine,
{5-cyclobutyl-1H-pyrazol-3-yl)-(4-methoxy-phenyl)-amine; pyridine-2-carboxylic acid . {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}-
cyclopentyl}-amide; 3-triftuoromethy!-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl]- cyclopentyl}-benzamide; oo. oo 15 : cyclobutanecarboxylic acid {3-[5-(3-trifluoromethyi-phenytamino)-2H-pyrazol-3-ylj- cyclopentyl}-amide; 2 ,2-dimethyl-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi}-cyclopentyt}- propionamide; 4-fluoro-N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yl}-cyclopenty!}- benzamide; 2,2,2-trifluoro-N-{3-[5-(3-trifluoromethyi-phenylamino)-2H-pyrazoi-3-yil-cyclopentyl}- acetamide; cyclopropanecarboxylic acid {3-[5-(3-triflucromethyl-phenylaminc)-2H-pyrazol-3-ylj- cyciopentyl}-amide; N-{3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi]-cyclopentyl}-propionamide; cyclohexanecarboxylic acid {3-[5-(3-trifluoromethyl-phenylamino)-2H-pyrazol-3-yi}- cyclopentyl}-amide; N-[5-(3-acetylamino-cyclopentyl)-2H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide; cyclopropanecarboxylic acid {3-[5-(2-naphthalen-1-yl-acetylamino)-1H-pyrazol-3-yi}- cyclopentyl}-amide; ’ 2-naphthalen-1-yl-N-{5-[3-(2,2,2-trifluoro-acetylamino)-cyclopentyi]-2H-pyrazol-3-yl}- acetamide; ) N-{3-[5-(2-naphthalen-1-yl-acetylamino)- 1H-pyrazol-3-ylj-cyciopentyl}-benzamide; N-(5-hydroxymethyl-1H-pyrazol-3-yl)-2-naphthalen-1-yl-acetamide; 2-naphthalen-1-ylI-N-{5-(thiazol-2-ylaminomethy!)- 1H-pyrazol-3-yl}-acetamide; N-[5-((1S)-hydroxy-ethyl)-2H-pyrazol-3-yl}-2-naphthalen- 1-yl-acetamide;
N-{5-[(1S)~(benzooxazoal-2-yloxy)-ethyl]-1H-pyrazol-3-yi}-2-naphthalen-1-yi- ) acetamide; N-{5-[(1S)-(benzothiazol-2-yioxy)-ethyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl- i acetamide;
N-[5-(3-hydroxy-1-methyl-propyl)-1H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide; N-[5-(benzothiazol-2-yloxymethyl)-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide; N-{5-[3-(benzothiazol-2-yloxy)-1-methyl-propyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl-
acetamide; N-[5-(2-hydroxy-(1S)-methyi-ethyl)-2H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide; N-{5-](1R)-(benzathiazol-2-yloxy)-ethyi]-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide; N-[5-(3-acetylamino-1-methyl-propyl)-1H-pyrazol-3-yl}-2-naphthalen-1-yl-acetamide; 3-methoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yll-cyclobutyl}- benzamide; oo N-{5-(cis-3-acetylamino-cyclobutyl)-1H-pyrazol-3-yl]-2-naphthalen-1-yl-acetamide; N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}-cyclobutyl}-benzamide; 2-cyclopropyl-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- cyclobutyl}-acetamide; 6-chloro-pyridine-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl}-cyclobutyl}-amide; quinoline-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide; pyrazine-2-carboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-amide; 4-methoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}- benzamide; N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]-cyclobutyl}-3-nitro- benzamide; N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yi}-cyclobutyl}-3- trifluoromethyl-benzamide; i N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino}-2H-pyrazol-3-yl}-cyclobutyl}- isobutyramide; ' 2-phenyl-cyclopropanecarboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-vylil-cyclobutyl}-amide; N-{5-[cis-3-(benzooxazol-2-yloxy)-cyclobutyi}-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide;
4-dimethylamino-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl}- cyclobutyl}-benzamide; 3,5-dimethoxy-N-{cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H-pyrazol-3-yl]- ) cyclobutyl}-benzamide; 2-naphthalen-1-yI-N-[5-(cis-3-phenyl-cyclobutyl})-2H-pyrazol-3-yl]-acetamide; N-{5-[cis-3-(3-methoxy-phenyl)-cyclobutyi]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; N-{5-[cis-3-(4-methoxy-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1-yl-N-[5-(cis-3-p-tolyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-{5-[cis-3-(4-chloro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-naphthalen-1-yi- acetamide; oo oo 15 2-(4-methoxy-phenyl)-N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl}-2H-pyrazol-3-yi}- acetamide; N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl}-2H-pyrazol-3-y1}-2-phenyl-acetamide; N-{5-[cis-3-(2-methoxy-phenyl)-cyclobutyl}-2H-pyrazol-3-yi}-2-pyridin-3-yl-acetamide; N-{5-[cis-3-(4-methoxy-phenyl)-cyclobutyl]-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; 2-quinolin-6-yI-N-[5-(cis-3-p-tolyl-cyclobutyl)-1H-pyrazol-3-yl]-acetamide; N-{5-[cis-3-(4-fiuoro-phenyl)-cyclobutyil-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[cis-3-(4-chloro-phenyl)-cyclobutyl}-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; 2-quinolin-6-yl-N-[5-(cis-3-m-tolyl-cyclobutyl)-1H-pyrazol-3-yl}-acetamide; 4-dimethylamino-N-{cis-3-[5-(2-naphthalen- 1 -yl-acetylamino)-2H-pyrazol-3-yl]- cyclobutyl}-benzamide; 2-naphthalen-1-yl-N-{5-{cis-3-(pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-acetamide; 6-methyl-pyridine-2-carboxylic acid {cis-3-[5-{2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl]-cyciobutyl}-amide; 2-phenyl-cyclopropanecarboxylic acid methyl-{cis-3-[5-(2-naphthalen-1-yl- i acetylamino)-2H-pyrazol-3-yi}-cyclobutyl}-amide; N-{5-[cis-3-(3-methyl-pyrazin-2-yloxy)-cyclobutyl]- 1 H-pyrazol-3-yl}-2-naphthalen-1-yi- ) acetamide; {5-[cis-3-(2-methoxy-phenyl)-cyclobutyl}-1H-pyrazol-3-yl}-(6-methoxy-pyridin-2-yl)- amine;
N-{5-[cis-3-(3,8-dimethyl-pyrazin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthaien- 1-yl-acetamide; N-{5-[cis-3-(3-methoxy-pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1- ’ yl-acetamide; 2-methyl-cyclopropanecarboxylic acid {cis-3-[5-(2-naphthalen-1-yl-acetylamino)-2H- pyrazol-3-yl}-cyclobutyl}-amide; 2-naphthaien-1-yl-N-{5-[cis-3-(3-trifluoromethyl-pyridin-2-yloxy)-cyclobutyi]- 1H- pyrazol-3-yl}-acetamide; 2-naphthalen-1-yl-N-{5-[cis-3-(3-nitro-pyridin-2-yloxy)-cyclobuty!}- ~~ 1H-pyrazol-3-yl}- acetamide; N-{5-[cis-3-(benzathiazol-2-yloxy)-cyclobutyl}-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1-yl-N-{5-[cis-3-(4-trifluoromethyl-pyrimidin-2-yloxy)- cyclobutyl]-1H- pyrazol-3-yl}-acetamide; - oo 15 2-naphthalen-1-yl-N-{5-[3-(5-nitro-pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}- acetamide; 2-naphthalen-1-yl-N-{5-[3-(pyrimidin-2-yloxy)-cyclobutyl}- 1H-pyrazol-3-yf}-acetamide; 2-naphthaien-1-yl-N-{5-{3-(5-trifluoromethyl-pyridin-2-yloxy)- cyclobutyl}-1H-pyrazol-3- yl}-acetamide; N-{5-[3-(6-methoxy-pyridazin-3-yloxy)-cyclobutyl]-1H-pyrazol-3-yi}-2-naphthalen-1-yl- acetamide; 2-naphthalen-1 -yl-N-{5-[3-(pyrazin-2-yloxy)-cyclobutyi}-1 H-pyrazol-3-yl}-acetamide; N-{5-[3-(6-methyl-pyridin-2-yloxy)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yl- acetamide; N-{5-[3-(6-chloro-benzothiazol-2-yloxy)-cyclobutyl}-1H-pyrazol-3-yl}-2-naphthalen-1- yl-acetamide; N-{5-[3-(6-methoxy-benzothiazol-2-yloxy)-cyclobutyl]-1H-pyrazoi-3-yi}-2-naphthalen- 1-yl-acetamide; N-{5-[cis-3-(4-Hydroxy-phenyl)-cyclobutyl]-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[cis-3-(3-Hydroxy-phenyl)-cyclobutyl}-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; . 2-Naphthalen-1 -yl-N-[5-(cis-3-pyridin-3-yl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-[5-(cis-3-Naphthalen-2-yl-cyclobutyl)-2H-pyrazol-3-yl]-2-pyridin-3-yl-acetamide; ’ N-(5-indan-2-yl-1H-pyrazol-3-yl)-2-quinolin-6-yl-acetamide; N-[5-(cis-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazot-3-yl}-2-quinolin-6-yl-acetamide; N-[5-(cis-3-Pyridin-2-yl-cyclobutyl)-2H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; 2~(4-Methoxy-phenyl)-N-[5-(cis-3-pyridin-4-yl-cyclobutyl)-2H-pyrazol-3-yl}-acetamide;
N-{5-[3-(cis-2-Dimethylaminomethyl-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; N-(5-{cis-3-[3-(2-Dimethylamino-ethoxy)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- ’ methoxy-phenyl)-acetamide; N-{5-{cis-3-(2-Hydroxy-pheny!)-cyciobutyl}-2H-pyrazol-3-yi}-2-(4-methoxy-phenyl)- acetamide; N-(5-{cis-3-[2-(2-Dimethylamino-ethoxy)-phenyl}-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-[5-(cis-3-phenyl-cyclobutyl)-2H-pyrazol-3-yl]-acetamide; N-{5-[cis-3-(2-Fluoro-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-pheny!)- acetamide; N-(5-{cis-3-[4-(Azetidin-3-yloxy)-phenyl}-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy- phenyl)-acetamide; N-(5-{cis-3-[2-(Azetidin-3-yloxy}-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4-methoxy~ . . E 15 phenyl)-acetamide: 2-(4-Methoxy-phenyl)-N-{5-[cis-3-(2-methylsulfanyl-phenyl)-cyclobuty!]-2H-pyrazol-3- yi}-acetamide; N-{5-[cis-3-(2-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[cis-3-(4-Cyano-phenyl}-cyclobutyl}-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- acetamide; N-{5-[cis-3-(2-Cyano-phenyl)-3-hydroxy-cyclobuty!}-2H-pyrazoi-3-yi}-2-(4-methoxy- phenyl)-acetamide; N-{5-[cis-3-(2-Hydroxy-ethyl)-cyclobutyl]-1H-pyrazol-3-yl}-2-naphthalen-1-yi- acetamide; N-{5-[cis-3-(3-Cyano-phenyl)-cyclobutyl}-2H-pyrazol-3-yi}-2-(4-methoxy-phenyi)- acetamide; N-{5-[cis-3-(2-Cyano-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyil)- acetamide; . N-{5-[cis-3-(3-Amino-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy-phenyl)- ’ acetamide; 4-~(cis-3-{5-[2-(4-Methoxy-phenyl)-acetylamino}-1H-pyrazol-3-yl}-cyclobutyl)-benzoic ' acid methyl ester; N-{5-[cis-3-(4-Hydroxymethyl-pheny!)-cyclobutyl]-2H-pyrazol-3-y1}-2-(4-methoxy- phenyl}-acetamide; N-{5-[cis-3-(2-Hydroxy-phenyl)-cyclobutyl}-1H-pyrazol-3-yl}-2-phenyl-acetamide;
N-{5-[cis-3-(2-Hydroxy-pheny!)-cyclobutyl}-1H-pyrazol-3-yl}-2-quinolin-6-yl-acetamide; N-{5-[cis-3-(2-Hydroxy-phenyl)-cyclobutyl]-1H-pyrazol-3-yl}-acetamide; Cyclopropanecarboxylic acid {5-[cis-3-(2-hydroxy-phenyl)-cyclobutyl}-1H-pyrazol-3- ’ yl}-amide; 5} N-{5-[cis-3-(2-Hydroxy-phenyl)-cyclobutyl]-1H-pyrazol-3-yl}-isobutyramide; N-{5-[cis-3-(3-Aminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; N-{5-[cis-3-(3-Dimethylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 3-(cis-3-{5-[2-(4-Methoxy-phenyl)-acetylamino]-1H-pyrazol-3-yl}-cyclobutyl)-benzoic acid methyl ester; N-{5-[cis-3-(3-Hydroxymethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- phenyl}-acetamide; N-(5-{cis-3-[3-(1-Hydroxy-1-methyl-ethyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- EE : methoxy-phenyl)-acetamide; N-{5-[cis-3-(3-Ethylaminomethyl-phenyl)-cyclobutyi}-2H-pyrazol-3-yi}-2-(4-methoxy- phenyl)-acetamide; N-{5-[cis-3-(3-Cyclobutylaminomethyl-phenyl)-cyclobutyl]-2H-pyrazol-3-yi}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[cis-3-(3-propylaminomethyl-phenyl)-cyclobutyl]-2H- pyrazol-3-yl}-acetamide; N-{5-[cis-3-(3-Cyclopentylaminomethyl-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; N-(5-{cis-3-[3-(Benzylamino-methyl)-phenyl]-cyclobutyl}-2H-pyrazol-3-yl)-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-{3-(3-methylaminomethyi-phenyl)-cyclobutyl}-2H-pyrazol- 3-yl}-acetamide; N-{5-[cis-3-(3-Cyclopropylaminomethyl-phenyl)-cyclobutyl}-2H-pyrazol-3-yl}-2-(4- methoxy-phenyl)-acetamide; 2-(4-Methoxy-phenyl)-N-{5-[cis-3-(3-pyrrolidin-1-yimethyl-phenyl)-cyclobutyl]-2H- ’ pyrazol-3-yl}-acetamide; N-{5-[cis-3-(3-Diethylaminomethyl-pheny!)-cyclobutyl]-2H-pyrazol-3-yl}-2-(4-methoxy- : phenyl)-acetamide; N-{5-[cis-3-(3-Azetidin-1-ylmethyl-phenyl)-cyclobutyl]-2 H-pyrazol-3-yl}-2-(4-methoxy- phenyl)-acetamide; and pharmaceutically acceptable salts of the foregoing compounds.
-g2-
10. A pharmaceutical composition for treating a disease or condition comprising ) abnormal cell growth or a neurodegenerative disease or condition in a mammal comprising a compound of claim 1 in an amount effective in treating said disease or condition, and a ’ pharmaceutically acceptable carrier.
11. A pharmaceutical composition for treating a disease or condition in a mammal the treatment of which can be effected or facilitated by altering dopamine mediated neurotransmission comprising a compound of claim 1 in an amount effective in treating said disease ar condition or in an amount effective to inhibit cdk5 activity, and a pharmaceuticaily acceptable carrier.
12. A pharmaceutical composition for treating in a mammal a disease or condition selected from male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb SL a. 15 immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency, comprising a compound of claim 1 in an amount effective in treating said disease or condition, and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a compound according to claim 1 and a second member selected from the group consisting of an SSRI, an NK-1 receptor antagonist, a 5HT,, antagonist, - ziprasidone, olanzapine, risperidone, L-745870, sonepiprazole, RP 62203, NGD 941, balaperidone, flesinoxan, gepirone, an acetylcholinesterase inhibitor, TPA, NIF, a potassium channel modulator such as BMS- 204352, and an NMDA receptor antagonist, wherein the cdk5 inhibitor and the second member are together in an effective amount, and a pharmaceutically acceptable carrier.
14. A compound of the formula Ne Prot Te 0 NH, R? O— l : wherein Prot is a protecting group; i R?is H, F, -CH,, -CN, or -C(=O)OR’; and n is an integer selected from 1, 2, 3, and 4.
ZA200301064A 2000-08-31 2003-02-07 Pyrazole derivatives and their use as protein kinase inhibitors. ZA200301064B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
ZA200301064B true ZA200301064B (en) 2004-04-19

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301064A ZA200301064B (en) 2000-08-31 2003-02-07 Pyrazole derivatives and their use as protein kinase inhibitors.

Country Status (38)

Country Link
EP (1) EP1313710A1 (en)
JP (1) JP2004507526A (en)
KR (1) KR20030027093A (en)
CN (1) CN1518543A (en)
AP (1) AP2001002266A0 (en)
AR (1) AR035345A1 (en)
AU (1) AU2001280009A1 (en)
BG (1) BG107455A (en)
BR (1) BR0113574A (en)
CA (1) CA2420363A1 (en)
CR (1) CR6881A (en)
CZ (1) CZ2003468A3 (en)
DO (1) DOP2001000243A (en)
DZ (1) DZ3398A1 (en)
EA (1) EA200300205A1 (en)
EC (1) ECSP034480A (en)
EE (1) EE200300085A (en)
GT (1) GT200100179A (en)
HN (1) HN2001000192A (en)
HR (1) HRP20030140A2 (en)
HU (1) HUP0302669A3 (en)
IL (1) IL154016A0 (en)
IS (1) IS6687A (en)
MA (1) MA26946A1 (en)
MX (1) MXPA03001785A (en)
NO (1) NO20030958D0 (en)
NZ (1) NZ523656A (en)
OA (1) OA12368A (en)
PA (1) PA8528101A1 (en)
PE (1) PE20020470A1 (en)
PL (1) PL360742A1 (en)
SK (1) SK2002003A3 (en)
SV (1) SV2002000618A (en)
TN (1) TNSN01132A1 (en)
UY (1) UY26909A1 (en)
WO (1) WO2002018346A1 (en)
YU (1) YU14703A (en)
ZA (1) ZA200301064B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (en) 1999-01-13 2012-05-15 Bayer Healthcare Llc OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100876069B1 (en) 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
MXPA03005610A (en) 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
DK1441724T3 (en) * 2001-09-27 2007-12-03 Serono Lab Method for increasing endogenous testosterone levels
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
ES2304531T3 (en) * 2002-07-17 2008-10-16 Pfizer Italia S.R.L. HETEROBICICLIC DERIVATIVES OF PIRAZOL AS QUINASA INHIBITORS.
WO2004033434A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
US7582630B2 (en) * 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
ATE410415T1 (en) 2003-02-27 2008-10-15 Smithkline Beecham Corp NEW CONNECTIONS
PT1636585E (en) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diaryl ureas with kinase inhibiting activity
CA2528496C (en) * 2003-06-05 2011-04-12 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
CA2532965C (en) * 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
JP4777887B2 (en) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション Fluoro-substituted omegacarboxyaryl diphenylureas for the treatment and prevention of diseases and conditions
MXPA06000933A (en) * 2003-07-25 2006-03-30 Pfizer Aminopyrazole compounds and use as chk1 inhibitors.
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7521560B2 (en) 2004-06-29 2009-04-21 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
KR20070086188A (en) 2004-11-17 2007-08-27 미카나 테라퓨틱스, 인크. Kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
PT2383268E (en) 2005-02-04 2015-12-21 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006085685A1 (en) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Pyrazole compound
PT1853588E (en) 2005-02-16 2008-08-25 Astrazeneca Ab Chemical compounds
KR20080015409A (en) 2005-05-16 2008-02-19 아스트라제네카 아베 Chemical compounds
EP1741708A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
BRPI0616630B8 (en) 2005-09-30 2021-05-25 Miikana Therapeutics Inc substituted pyrazole compounds
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1951715B1 (en) 2005-11-03 2013-09-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
CN105664141A (en) 2006-10-18 2016-06-15 派利尼斯有限公司 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
RU2009119181A (en) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS Glycogen synthase-kinase-3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2129381A1 (en) 2007-01-24 2009-12-09 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
BRPI0814423B1 (en) 2007-07-17 2022-04-19 Plexxikon, Inc Kinase modulating compounds and pharmaceutical composition comprising the same
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
EP2727910B1 (en) 2007-09-21 2016-03-16 Array Biopharma, Inc. Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators
JPWO2009130900A1 (en) * 2008-04-24 2011-08-11 日本曹達株式会社 Oxime derivatives, intermediate compounds and plant disease control agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR078033A1 (en) 2009-04-03 2011-10-12 Plexxikon Inc A SOLID DISPERSION, CONTAINING THE COMPOUND {3- [5- (4- (CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDA OF PROPANE-1-SULPHONIC ACID, COMPOSITIONS AND FORMULATIONS THAT INCLUDE SUCH SOLID DISPERSION; METHODS FOR MANUFACTURING SUCH SOLID DISPERSION, FORMS 1 AND 2
JP2013506691A (en) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole inhibitors of phosphatidylinositol 3-kinase
ES2633317T3 (en) 2009-11-06 2017-09-20 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications for it
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
MA34948B1 (en) 2011-02-07 2014-03-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP3033339B1 (en) * 2013-08-16 2018-02-28 Merck Patent GmbH 3-substituted cyclopentylamine derivatives
CN106580986B (en) * 2016-11-28 2017-09-15 王保亮 A kind of pharmaceutical composition for treating teen bra
JP2022516057A (en) 2018-12-31 2022-02-24 バイオメア フュージョン，エルエルシー Irreversible inhibitor of menin-MLL interaction
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CU20210065A7 (en) * 2019-01-31 2022-04-07 Pfizer 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS THAT HAVE INHIBITORY ACTIVITY ON CDK2
WO2022135442A1 (en) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2 inhibitor and preparation method therefor
WO2023278326A1 (en) 2021-06-28 2023-01-05 Blueprint Medicines Corporation Cdk2 inhibitors
WO2023274397A1 (en) * 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Cdk2 inhibitor, preparation method therefor and use thereof
EP4387972A1 (en) 2021-08-20 2024-06-26 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023083201A1 (en) * 2021-11-09 2023-05-19 上海拓界生物医药科技有限公司 Aminopyrazole derivative, and preparation method therefor and use thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002618T2 (en) * 1997-12-22 2001-04-20 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
KR100579792B1 (en) * 1998-05-13 2006-05-12 동화약품공업주식회사 Novel 2,5-pyridinedicarboxylic acid derivatives
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
WO2001007411A1 (en) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
DE60023012T2 (en) * 1999-08-12 2006-07-20 Pharmacia Italia S.P.A. 3 (5) -AMINO-PYRAZOL DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF AS CANCER-INGREDIENT MEDICAMENTS
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
ATE315036T1 (en) * 1999-11-30 2006-02-15 Pfizer Prod Inc 2,4-DIAMINOPYRIMIDENE DERIVATIVES AS IMMUNOSUPPRESSANTS
WO2001079198A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase

Also Published As

Publication number Publication date
JP2004507526A (en) 2004-03-11
HN2001000192A (en) 2001-08-28
IS6687A (en) 2003-01-16
SK2002003A3 (en) 2004-04-06
CN1518543A (en) 2004-08-04
IL154016A0 (en) 2003-07-31
CZ2003468A3 (en) 2004-05-12
MXPA03001785A (en) 2003-06-04
DOP2001000243A (en) 2002-10-15
EE200300085A (en) 2004-12-15
EP1313710A1 (en) 2003-05-28
DZ3398A1 (en) 2002-03-07
BR0113574A (en) 2003-07-22
ECSP034480A (en) 2003-03-31
NO20030958L (en) 2003-02-28
NO20030958D0 (en) 2003-02-28
UY26909A1 (en) 2002-03-22
YU14703A (en) 2006-05-25
HUP0302669A2 (en) 2003-12-29
BG107455A (en) 2003-09-30
CA2420363A1 (en) 2002-03-07
WO2002018346A1 (en) 2002-03-07
PE20020470A1 (en) 2002-06-18
SV2002000618A (en) 2002-10-24
NZ523656A (en) 2004-11-26
OA12368A (en) 2004-04-13
HUP0302669A3 (en) 2004-03-29
EA200300205A1 (en) 2003-06-26
CR6881A (en) 2004-03-11
KR20030027093A (en) 2003-04-03
PL360742A1 (en) 2004-09-20
AR035345A1 (en) 2004-05-12
PA8528101A1 (en) 2002-07-30
AP2001002266A0 (en) 2001-09-30
MA26946A1 (en) 2004-12-20
HRP20030140A2 (en) 2003-04-30
TNSN01132A1 (en) 2005-11-10
GT200100179A (en) 2002-04-22
AU2001280009A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
ZA200301064B (en) Pyrazole derivatives and their use as protein kinase inhibitors.
ZA200300819B (en) Imidazole derivatives.
US20050209297A1 (en) Pyrazole derivatives
JP5460589B2 (en) Sodium channel inhibitor
US8492545B2 (en) Aminothiazole compounds as kinase inhibitors and methods of using the same
US20060149066A1 (en) Imidazole derivatives
WO2008023239A1 (en) Pyrimidone compounds as gsk-3 inhibitors
BRPI0806665A2 (en) nicotinic acetylcholine receptor modulating compounds, pharmaceutical composition and use thereof
US20020103185A1 (en) Pyrazole derivatives
EP2164494A1 (en) Methods of treatment
US20030083352A1 (en) Synthesis of imidazole intermediates